FRI Selected with Chase Brexton Health Care as One of Five Sites for the CTN 0101 Trial

Friends Research Institute (FRI) and its clinical collaborators at Chase Brexton Health Care are serving as one of the five sites in a National Institute of Drug Abuse (NIDA) Clinical Trials Network study, entitled the Subthreshold Opioid Use Disorder Prevention (STOP) trial. Research personnel at FRI will assist with the conduct of the study.

The study tests a collaborative care intervention that aims to reduce risky opioid use in adult primary care patients who do not have moderate-severe opioid use disorder. Risky opioid use is defined as nonmedical use of prescribed opioids (taking a higher dose or taking an opioid more frequently than prescribed), any use of illicit opioids, or taking pharmaceutical opioids that were not prescribed to the individual taking them. In this cluster randomized trial, enrolled patients of participating primary care providers will be randomly assigned to the STOP intervention vs. enhanced usual care condition, and followed for 12 months. In the intervention, patient participants will receive support from a nurse care manager and a telephone health coach, as well as brief advice from their primary care provider. Findings from the study will shed light on the efficacy of a collaborative care model to reduce days of risky opioid use, and potentially to prevent opioid use disorder and other opioid-related health problems, in primary care.